Patient with atopic dermatitis, hyper <scp>IgE</scp> syndrome and ulcerative colitis, treated successfully with dupilumab during pregnancy
Inés Gracia‐Darder, Jaime Pons De Ves, Miguel Reyero Cortina, A. Martín‐Santiago
Abstract
The data that support the findings of this study are available from the corresponding author upon reasonable request. Figure S1 A) Eczematous lesions of the patient, prior to starting dupilumab. It can be seen multiple confluent erythematous-brownish lichenified plaques on trunk, neck, and extremities. B) Improvement of cutaneous lesions at 16 weeks of treatment with a SCORAD of 15/103. C) Disappearance of lichenification after 40 weeks of treatment. At that time, the patient was already 5 weeks pregnant. D) The patient at 35 weeks of gestation, having been treated with dupilumab for 75 weeks with a SCORAD of 8/103 Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.